Placental derived mesenchymal stem cell therapy - Osiris Therapeutics

Drug Profile

Placental derived mesenchymal stem cell therapy - Osiris Therapeutics

Alternative Names: Grafix; Grafix CORE; Grafix cryopreserved placental membrane; Grafix PRIME; Grafix XC; hCVPM - Osiris Therapeutics; Human cryopreserved viable placental membrane - Osiris Therapeutics; Mesenchymal stem cell therapy - Osiris Therapeutics; OTI-15-01; OTI-15-02

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Osiris Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Wounds

Most Recent Events

  • 01 Jun 2017 Osiris Therapeutics terminates a phase III trial for Wounds (chronic diabetic foot ulcer) in USA, due to company's desire to allocate more research and development resources to other clinical programs (NCT02571738)
  • 06 Oct 2016 Efficacy data from a phase IV trial in Diabetic foot ulcer released by Osiris Therapeutics
  • 12 Apr 2016 Pharmacodynamics data from a preclinical study was released by Osiris Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top